Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more) Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Minerlaization (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assertio Holdings Inc ASRT

Healthcare Biotechnology
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and... see more

Recent & Breaking News (NDAQ:ASRT)

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 3, 2025

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

GlobeNewswire December 17, 2024

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

GlobeNewswire December 13, 2024

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

GlobeNewswire December 12, 2024

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

GlobeNewswire December 6, 2024

Assertio Reports Third Quarter 2024 Financial Results

GlobeNewswire November 11, 2024

Assertio Provides Response to Letter from Short-seller

GlobeNewswire November 11, 2024

Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024

GlobeNewswire October 30, 2024

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

GlobeNewswire October 11, 2024

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2024

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

GlobeNewswire September 3, 2024

Assertio Reports Second Quarter 2024 Financial Results

GlobeNewswire August 7, 2024

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

GlobeNewswire July 24, 2024

Kuehn Law Encourages Investors of Assertio Holdings, Inc. to Contact Law Firm

Newsfile July 22, 2024

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire July 9, 2024

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 6, 2024

Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024

GlobeNewswire June 5, 2024

Assertio Announces the Appointment of Brendan P. O'Grady as New CEO

GlobeNewswire May 29, 2024

Assertio to Participate in Benchmark Healthcare Conference on May 21-22

GlobeNewswire May 17, 2024

BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS

PR Newswire May 17, 2024